Patent · US Active

Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine

US9156812B2 · kind B2 · utility

3Cited by

26References

7Claims

0Family size

Assignees

Bristol-Myers Squibb Company · US
ALBANY MOLECULAR RESEARCH, INC. · US

Inventors

Jun Qiu · Kendall Park, US
Qi Gao · Shanghai, CN
Shuang Liu · Schenectady, US
Min Hu · Schenectady, US
Yuh-Lin Allen Yang · Baoshan, TW
Matthew Isherwood · Amherst, US
Rasidul Amin · East Greenbush, US

Key dates

Filing date	Mar 18, 2013
Grant date	Oct 13, 2015
Priority date	—
Expiry date	Dec 2, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D401/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.